EMA/FDA oncology approvals: adapt early-phase strategy fast

Published avril 5, 2025

Latest Article

Clinical strategy in oncology: rethink animal studies

juillet 30, 2025

Biotome and immunotherapy: a new predictive biomarker?

juillet 28, 2025

FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?

Rethinking phase 2 trials: beyond animal models

juillet 25, 2025

FDA has eased preclinical requirements

juillet 17, 2025

This simplified case study is inspired by real-world challenges. In practice, however, such situations often require a more advanced, matrix-based approach to support decision-making.

Why choose your target tumors early in preclinical stage ?

mai 17, 2025

Immunotherapies and early-phase trials: what’s next for phase 1/2?

mai 1, 2025

Need Help?

Call Us

P: +41 79 624 79 55

F: +41 21 601 19 38

Company

Contact Info

Copyright © 2025 MEDExpansion, All rights reserved. Powered by Web&Vous